Evidence, incentives, and device proliferation

Harlan examines LVAD trial evidence, harms, financial incentives, and how reimbursement and industry ties sped adoption.

Play episode from 31:40

chevron_right

Transcript

chevron_right

Transcript

Episode notes

Howie and Harlan are joined by Scott Berkowitz '03, cardiologist and chief population health officer at Johns Hopkins Medicine, to discuss the necessity of moving from fee-for-service to value-based care delivery to improve outcomes for all. Harlan highlights the dangers of misinformation about Ivermectin. Howie reports on the potential conflicts of interest created by device manufacturers' payments to cardiologists.

Links:

Johns Hopkins Medicine: Home

Johns Hopkins Community Health Partnership

"Association of a Care Coordination Model With Health Care Costs and Utilization"

"Planning for the Future of Population Health: The Johns Hopkins Medicine Experience"

"Califf's long day on Capitol Hill"

"The FDA Deleted Its Viral Ivermectin Tweets. Now There's Even More Misinformation."

"Philly Nonprofit Awarded $48 Million to Apply AI in Search for New Uses for Approved Drugs

Posted on March 12, 2024"

"Effect of Early Treatment with Ivermectin among Patients with Covid-19"

"Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19"

"Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19"